388 related articles for article (PubMed ID: 32020727)
1. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
[TBL] [Abstract][Full Text] [Related]
3. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Garg S; Unnithan R; Hansen KE; Costedoat-Chalumeau N; Bartels CM
Arthritis Care Res (Hoboken); 2021 May; 73(5):707-716. PubMed ID: 32004406
[TBL] [Abstract][Full Text] [Related]
11. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
[TBL] [Abstract][Full Text] [Related]
12. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
14. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Int J Rheum Dis; 2019 Mar; 22(3):468-472. PubMed ID: 30406967
[TBL] [Abstract][Full Text] [Related]
15. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
Takamasu E; Yokogawa N; Shimada K; Sugii S
Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
[TBL] [Abstract][Full Text] [Related]
16. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa Y; Oiwa H
Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
Wakiya R; Kameda T; Ueeda K; Nakashima S; Shimada H; Mansour MF; Kato M; Miyagi T; Miyatake N; Kadowaki N; Dobashi H
Lupus; 2019 Jun; 28(7):826-833. PubMed ID: 31068068
[TBL] [Abstract][Full Text] [Related]
18. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
19. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
Ichikawa K; Kirino Y; Kunishita Y; Kishimoto D; Takase-Minegishi K; Yoshimi R; Nakajima H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):259-264. PubMed ID: 33533686
[TBL] [Abstract][Full Text] [Related]
20. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
